Tocilizumab
Brand: RoActemra®
NICE TA: 518
Indication: Treating giant cell arteritis (NICE TA518)
Disease category: Musculoskeletal system
Commissioning responsibility: NHS England
PbR excluded: Yes
Background
Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults, only if:
• they have relapsing or refractory disease
• they have not already had tocilizumab
• tocilizumab is stopped after 1 year of uninterrupted treatment at most and
• the company provides it with the discount agreed in the patient access scheme.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
Decisions of Lancashire local decision making groups:
NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |